These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 32783382)

  • 1. Effects of BAFF Neutralization on Atherosclerosis Associated With Systemic Lupus Erythematosus.
    Saidoune F; Even G; Lamri Y; Chezel J; Gaston AT; Escoubet B; Papo T; Charles N; Nicoletti A; Sacre K
    Arthritis Rheumatol; 2021 Feb; 73(2):255-264. PubMed ID: 32783382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers.
    Figgett WA; Deliyanti D; Fairfax KA; Quah PS; Wilkinson-Berka JL; Mackay F
    J Autoimmun; 2015 Jul; 61():9-16. PubMed ID: 26027434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B Cell-Activating Factor Neutralization Aggravates Atherosclerosis.
    Tsiantoulas D; Sage AP; Göderle L; Ozsvar-Kozma M; Murphy D; Porsch F; Pasterkamp G; Menche J; Schneider P; Mallat Z; Binder CJ
    Circulation; 2018 Nov; 138(20):2263-2273. PubMed ID: 29858401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
    Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
    Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutting Edge: BAFF Overexpression Reduces Atherosclerosis via TACI-Dependent B Cell Activation.
    Jackson SW; Scharping NE; Jacobs HM; Wang S; Chait A; Rawlings DJ
    J Immunol; 2016 Dec; 197(12):4529-4534. PubMed ID: 27837104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cell activating factor and related genetic variants in lupus related atherosclerosis.
    Theodorou E; Nezos A; Antypa E; Ioakeimidis D; Koutsilieris M; Tektonidou M; Moutsopoulos HM; Mavragani CP
    J Autoimmun; 2018 Aug; 92():87-92. PubMed ID: 29859654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
    Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TACI deletion protects against progressive murine lupus nephritis induced by BAFF overexpression.
    Arkatkar T; Jacobs HM; Du SW; Li QZ; Hudkins KL; Alpers CE; Rawlings DJ; Jackson SW
    Kidney Int; 2018 Oct; 94(4):728-740. PubMed ID: 29907458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-cell activating factor and A proliferation-inducing ligand in relation to intima-media thickness as biomarkers of premature atherosclerosis in systemic lupus erythematosus patients.
    Shater H; Fawzy M; Farid A; El-Amir A; Fouad S; Madbouly N
    Am J Med Sci; 2022 Nov; 364(5):646-654. PubMed ID: 35580639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel BAFF antagonist, BAFF-Trap, effectively alleviates the disease progression of systemic lupus erythematosus in MRL/lpr mice.
    Yu C; Chen S; Zhou B; Zhang H; Su X; Luo Y; Yang L
    Mol Immunol; 2021 Jan; 129():1-11. PubMed ID: 33254074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigations of a rabbit (Oryctolagus cuniculus) model of systemic lupus erythematosus (SLE), BAFF and its receptors.
    Yang J; Pospisil R; Ray S; Milton J; Mage RG
    PLoS One; 2009 Dec; 4(12):e8494. PubMed ID: 20041151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.
    Haselmayer P; Vigolo M; Nys J; Schneider P; Hess H
    Eur J Immunol; 2017 Jun; 47(6):1075-1085. PubMed ID: 28383107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor.
    Jacob CO; Yu N; Guo S; Jacob N; Quinn WJ; Sindhava V; Cancro MP; Goilav B; Putterman C; Migone TS; Stohl W
    Arthritis Rheum; 2013 Apr; 65(4):1043-54. PubMed ID: 23334904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: Regulation and underlying mechanisms.
    Rahman M; Sing S; Golabkesh Z; Fiskesund R; Gustafsson T; Jogestrand T; Frostegård AG; Hafström I; Liu A; Frostegård J
    Clin Immunol; 2016 May; 166-167():27-37. PubMed ID: 27102765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated B Cell, Toll-like, and BAFF Receptor Signals Promote Autoantibody Production by Transitional B Cells.
    Du SW; Jacobs HM; Arkatkar T; Rawlings DJ; Jackson SW
    J Immunol; 2018 Dec; 201(11):3258-3268. PubMed ID: 30373855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired HDL cholesterol efflux capacity in systemic lupus erythematosus patients is related to subclinical carotid atherosclerosis.
    Sánchez-Pérez H; Quevedo-Abeledo JC; de Armas-Rillo L; Rua-Figueroa Í; Tejera-Segura B; Armas-González E; Machado JD; García-Dopico JA; Jimenez-Sosa A; Rodríguez-Lozano C; Díaz-González F; González-Gay MA; Ferraz-Amaro I
    Rheumatology (Oxford); 2020 Oct; 59(10):2847-2856. PubMed ID: 32065639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus.
    Salazar-Camarena DC; Ortiz-Lazareno PC; Cruz A; Oregon-Romero E; Machado-Contreras JR; Muñoz-Valle JF; Orozco-López M; Marín-Rosales M; Palafox-Sánchez CA
    Lupus; 2016 May; 25(6):582-92. PubMed ID: 26424128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity.
    Vincent FB; Saulep-Easton D; Figgett WA; Fairfax KA; Mackay F
    Cytokine Growth Factor Rev; 2013 Jun; 24(3):203-15. PubMed ID: 23684423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TACI-dependent APRIL signaling maintains autoreactive B cells in a mouse model of systemic lupus erythematosus.
    Tran NL; Schneider P; Santiago-Raber ML
    Eur J Immunol; 2017 Apr; 47(4):713-723. PubMed ID: 28267197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocytic myeloid-derived suppressor cells contribute to IFN-I signaling activation of B cells and disease progression through the lncRNA NEAT1-BAFF axis in systemic lupus erythematosus.
    Dong G; Yang Y; Li X; Yao X; Zhu Y; Zhang H; Wang H; Ma Q; Zhang J; Shi H; Ning Z; Yan F; Zhai W; Dai J; Li Z; Li C; Ming J; Xue Q; Meng X; Si C; Xiong H
    Biochim Biophys Acta Mol Basis Dis; 2020 Jan; 1866(1):165554. PubMed ID: 31513833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.